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OBJECTIVES This study sought to evaluate the antiarrhythmic effects of lipid-lowering drug therapy as
assessed by ventricular tachyarrhythmia (ventricular tachycardia [VT]/ventricular fibrillation
[VF]) recurrences recorded by an implantable cardioverter defibrillator (ICD) in patients with
atherosclerotic heart disease (ASHD).
BACKGROUND Randomized trials of lipid-lowering drugs suggest reduction of sudden death (SD) in patients
with ASHD. Because SD is usually secondary to VT/VF, this observation suggests that
lipid-lowering therapy has antiarrhythmic effects.
METHODS The probability of VT/VF recurrence in patients with ASHD treated with an ICD in the
Antiarrhythmics Versus Implantable Defibrillators (AVID) trial who did not receive
lipid-lowering drug therapy (n  279) was compared with that in patients who received early
and consistent lipid-lowering therapy (n  83). In addition, all-cause mortality and cardiac
mortality of all patients in the AVID trial with ASHD who did not receive lipid-lowering
therapy (n  564) were compared with that of those who received early and consistent
lipid-lowering therapy (n  149).
RESULTS Using multivariate analyses, lipid-lowering therapy was associated with a reduction in the
relative hazard for VT/VF recurrence of 0.40 (95% confidence interval [CI] 0.15 to 0.58)
(adjusted p  0.003) in the ICD subgroup. Lipid-lowering therapy was also associated with
a reduction in the relative hazard for all-cause mortality of 0.36 (95% CI 0.15 to 0.68)
(adjusted p  0.03) and a reduction in the relative hazard for cardiac mortality of 0.39 (95%
CI 0.16 to 0.78) (adjusted p  0.04) in the larger study population.
CONCLUSIONS In patients with ASHD who have received an ICD, lipid-lowering therapy is associated with
reduction in the probability of VT/VF recurrence, suggesting that part of the benefit of
lipid-lowering therapy may be due to an antiarrhythmic effect. (J Am Coll Cardiol 2003;42:
81–7) © 2003 by the American College of Cardiology Foundation
Epidemiological studies have demonstrated a very clear
relationship between serum cholesterol levels and all-cause
mortality, in general, and atherosclerotic heart disease
(ASHD) mortality, in particular (1,2). The combined re-
sults of the randomized, controlled, mortality trials of
lipid-lowering using 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase inhibitors (3–7) have demon-
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strated a reduction in the relative risk of all-cause mortality
of 0.27 (95% confidence interval [CI] 0.21 to 0.33) and a
reduction in the relative risk of ASHD mortality of 0.28
(95% CI 0.20 to 0.35) in association with a reduction in
total serum cholesterol levels of 20%, a reduction in serum
LDL cholesterol of 23%, an elevation of HDL cholesterol
of 6%, and a reduction in serum triglycerides of 13% (3–7)
over a mean follow-up of 5.2 years. Two of these controlled
trials (3,6) have also reported a reduction in the relative risk
of sudden death (SD) with HMG-CoA reductase inhibitor
therapy. Combining their results suggests a reduction in the
relative risk of SD of 0.20 (95% CI 0.05 to 0.33) over a
mean follow-up of 5.4 years.
Of course, the reduction in SD mortality with lipid-
lowering therapy may simply reflect the well-recognized
effect of this therapy on coronary atherosclerosis. Neverthe-
less, the reduction in sudden cardiac death mortality asso-
ciated with such therapy has led to the hypothesis that
lipid-lowering has direct or indirect antiarrhythmic effects
against the ventricular tachyarrhythmias that are the most
common cause of SD. This hypothesis was first evaluated by
De Sutter et al. (8), who reported, from an observational
study of 78 patients with ASHD and life-threatening
ventricular tachycardia/ventricular fibrillation (VT/VF) who
were treated with an implantable cardioverter defibrillator
(ICD), that patients who received lipid-lowering therapy
had significantly fewer episodes of recurrent VT/VF than
did patients who had not received lipid-lowering therapy.
The purpose of the present analysis was to further evaluate
the possibility of an antiarrhythmic effect of lipid-lowering
therapy in the large, well-characterized, ICD patient pop-
ulation of the Antiarrhythmics Versus Implantable Defibril-
lator (AVID) trial.
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METHODS
The AVID trial was a prospective, multicenter, randomized
clinical trial comparing two strategies for the treatment of
patients who survived life-threatening, sustained VT/VF
(9,10). Briefly, patients resuscitated from VF, VT with
syncope, or sustained VT with a left ventricular ejection
fraction of 0.40 and symptoms of hemodynamic compro-
mise (near-syncope, dyspnea, angina) were randomized
either to receive pharmacologic antiarrhythmic therapy with
sotalol guided by the suppression of either spontaneous
ventricular arrhythmias or VT/VF inducible by pro-
grammed ventricular stimulation or with empiric amioda-
rone therapy (mostly the latter), or to receive an ICD. The
primary end point was all-cause mortality. The institutional
review board of each participating institution approved the
study. All patients gave written informed consent.
Patients who received an ICD had their device interro-
gated every three months for the duration of the trial and
when clinically indicated after therapy delivery. The ICD
interrogation record and corresponding clinical data were
forwarded to an ICD therapy events committee that classi-
fied each therapy as being appropriate or inappropriate
based upon historical and ICD-derived data. Relative to the
VT/VF recurrence events reported here, the ICD-derived
data included electrogram records for 76% of the events and
was limited to mean heart rate or sequential inter-
electrogram interval records for 24% of the events. For the
purposes of the present analysis, appropriate ICD therapy
delivery was considered to have represented a VT/VF
recurrence. All patient deaths in the AVID trial were
reviewed by an events committee and were classified as
being cardiac or noncardiac. Cardiac deaths were further
classified as being arrhythmic or nonarrhythmic. For the
purposes of the present analysis, patients with an arrhythmic
death were also considered to have had a VT/VF recurrence.
The prescription of lipid-lowering drug therapy in the
AVID trial was left to the discretion of the primary care
physician, and its use was recorded at discharge and at
follow-up visits as “yes” or “no.” Detailed medical therapy
histories were recorded from a sample of 237 (23%) of the
1,016 AVID patients. In this sample, 26% were prescribed
a lipid-lowering therapy—79% of which were HMG-CoA
reductase inhibitors, 19% were fibric acid derivatives, and
3% were bile acid resins. Serum cholesterol levels were not
measured. Five patterns of lipid-lowering therapy use dur-
ing the AVID trial were possible:
1) lipid-lowering therapy not used at any time;
2) lipid-lowering therapy used continuously;
3) lipid-lowering therapy started early (within 6 months of
follow-up) and then continued;
4) lipid-lowering therapy started early (within 6 months of
follow-up) and then discontinued early (within 12
months of follow-up); and
5) lipid-lowering therapy started late (after 9 months of
follow-up).
The combination of latency of the effects after starting
lipid-lowering therapy, the persistence of effects after stop-
ping lipid-lowering therapy, and the limited follow-up of
patients in the AVID trial suggested that the present
analysis include only those patients with one of the first
three patterns of lipid-lowering therapy use. The present
analysis was also limited to patients with ASHD (lipid-
lowering therapy was rarely prescribed to patients with other
forms of structural heart disease) and to patients who
survived at least one month after randomization to AVID
trial therapy (to allow for patient stabilization after the index
VT/VF event and to allow for lipid-lowering therapy
initiation).
Thus, the VT/VF-free survival analyses were performed
using all patients in the AVID trial with ASHD who had
received an ICD and survived one month after AVID
randomization, comparing subjects who had not received
lipid-lowering drug therapy with those subjects who re-
ceived early and consistent lipid-lowering drug therapy.
Hallstrom et al. (11) recently reported the baseline factors
that were predictive of VT/VF recurrence in the patients in
the AVID study who received an ICD—presenting arrhyth-
mia (VT vs. VF), history of cerebrovascular disease, lower
left ventricular ejection fraction, history of supraventricular
or ventricular tachyarrhythmias prior to the VT/VF, and the
absence of revascularization during the baseline hospitaliza-
tion. These factors were used to generate a hazard score for
VT/VF recurrence in each patient who received an ICD.
These individual hazard scores were adjusted for using Cox
proportional hazard methods when investigating the asso-
ciation between lipid-lowering therapy and time to VT/VF
recurrence. Total survival analyses and cardiac survival
analyses were also performed using all of the patients in the
AVID trial with ASHD who were randomized to receive an
ICD or antiarrhythmic drug therapy and survived at least
one month after AVID randomization, comparing subjects
who had not received lipid-lowering drug therapy with
those subjects who received early and consistent lipid-
lowering drug therapy.
Statistical analysis. Continuous data are presented as
mean  1 SD and were compared using Student t test.
Categorical data are presented as ratios (%) and were
compared using the chi-square statistic. Kaplan-Meier es-
timates were used to display VT/VF-free survival rates
Abbreviations and Acronyms
ASHD  atherosclerotic heart disease
AVID  Antiarrhythmics Versus Implantable
Defibrillator trial
CI  confidence interval
HMG-CoA  3-hydroxy-3-methylglutaryl coenzyme A
ICD  implantable cardioverter defibrillator
SD  sudden death
VF  ventricular fibrillation
VT  ventricular tachycardia
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within the ICD patient population and survival and cardiac
survival rates for the combined ICD and antiarrhythmic
drug patient populations. Cox proportional hazard methods
were used to adjust for baseline differences when investigat-
ing the association between the use of lipid-lowering ther-
apy and survival time. A two-tailed p value of 0.05 was
used to exclude the null hypothesis.
RESULTS
Study population. Of the 1,016 patients randomized in
the AVID study, 19 patients either died during the baseline
hospitalization or were still in hospital when the AVID
study was stopped. Of the remaining 997 patients, 187
patients did not have ASHD, and 18 patients died within
one month of randomization. Seventy-nine of the remain-
ing 792 patients were excluded, having received late (56
patients) or inconsistent (22 patients) lipid-lowering drug
therapy or because their lipid-lowering treatment status was
unknown (1 patient). Thus, the overall study group con-
sisted of 713 patients: 564 patients (79%) who did not
receive lipid-lowering drug therapy and 149 patients (21%)
who did receive lipid-lowering therapy. The ICD patient
study group was comprised of 362 patients who received an
ICD within one month of AVID randomization (349
patients from the randomized ICD arm and 13 patients
from the randomized antiarrhythmic drug treatment arm).
Of the ICD patient study group, 279 patients (77%)
received no lipid-lowering drug therapy, and 83 patients
(23%) received continuous (66 patients) or early (17 pa-
tients) lipid-lowering drug therapy.
The patient baseline demographic and clinical character-
istics for the ICD patient study group are displayed in Table
1. Patients receiving lipid-lowering drug therapy were
younger than were patients not receiving lipid-lowering
drug therapy. Furthermore, patients receiving lipid-
lowering drugs were also more likely to have sustained VT,
were less likely to have VF, and were less likely to be of
minority race than were patients not receiving lipid-
lowering drugs. Finally, patients receiving lipid-lowering
drugs were less likely to be female.
The patient baseline demographic and clinical character-
istics for the entire study group are displayed in Table 2.
Patients receiving lipid-lowering drugs were younger than
were those not receiving lipid-lowering drugs. Patients
receiving lipid-lowering drugs were also more likely to have
a history of myocardial infarction and to have a history of
hypertension. Patients receiving lipid-lowering drugs were
more likely to be discharged also receiving angiotensin-
converting enzyme inhibitor therapy, nitrate therapy, or
aspirin/antiplatelet therapy. Conversely, patients receiving
lipid-lowering therapy were less likely to be discharged
receiving digitalis therapy or to have received a revascular-
ization procedure during the baseline hospitalization.
Comparison of the Kaplan-Meier estimates of VT/VF-
free survival for patients who received an ICD within one
month of randomization showed improved VT/VF-free
survival for those patients on lipid-lowering drug therapy.
However, the difference did not reach statistical significance
(p  0.19). After adjustment for baseline inequities in the
hazard score for VT/VF recurrence, there was a statistically
significant association between time to VT/VF recurrence
and use of lipid-lowering drug therapy (adjusted p  0.003)
(Fig. 1). The reduction in relative hazard for VT/VF
recurrence associated with lipid-lowering drug therapy was
0.40 (95% CI 0.15 to 0.58). The proportion of VT/VF
recurrences that were attributed to VF was comparable in
the group of patients that received lipid-lowering therapy
(17%) and in the group of patients that did not receive
lipid-lowering therapy (16%).
Kaplan-Meier estimates of survival for the total study
group are shown in Figure 2. The univariate association
between survival and the use of lipid-lowering drugs was
statistically significant (p  0.02). Similar patterns of
survival as a function of use of lipid-lowering drug therapy
were seen in each of the randomized AVID treatment arms,
but the differences in the smaller subgroups did not reach
Table 1. Factors Used to Predict Ventricular Tachyarrhythmia Recurrence in ICD Patients
Attribute N Total LL Rx No LL Rx p Value
Age (yrs) 362 66  10 64  10 67  10 0.038
Female 362 60 (17%) 8 (10%) 52 (19%) 0.064
Non-white race 362 34 (9%) 0 (0%) 34 (12%) 0.000
LVEF 361 0.32  0.12 0.31  0.11 0.32  0.13 0.402
Baseline revascularization 362 43 (12%) 8 (10%) 35 (13%) 0.565
Arrhythmia prior to index VT/VF 362 170 (47%) 40 (48%) 130 (47%) 0.804
History of CVD 362 45 (12%) 13 (16%) 32 (11%) 0.343
Index arrhythmia 362 0.011
VF 135 (37%) 23 (28%) 112 (40%)
Documented VT, syncope 78 (22%) 14 (17%) 64 (23%)
Symptomatic sustained VT 149 (41%) 46 (55%) 103 (37%)
Data presented as mean  SD or N (%) for the total ICD patient population (Total), for the subgroup receiving lipid-lowering
drug therapy (LL Rx), and for the subgroup not receiving lipid-lowering therapy (no LL Rx). Revascularization indicates
revascularization procedure (coronary artery bypass grafting or percutaneous coronary intervention) after index VT/VF episode
that was accomplished prior to randomization in the AVID trial.
CVD  cerebrovascular disease; ICD  implantable cardioverter defibrillator; LVEF  left ventricular ejection fraction; VF
 ventricular fibrillation; VT  ventricular tachycardia.
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statistical significance (p  0.15 in the ICD arm, p  0.05
in the antiarrhythmic drug arm). Adjustment for inequities
in baseline determinants of survival (treatment arm, left
ventricular ejection fraction, VT vs. VF index arrhythmia,
history of renal disease, history of cerebrovascular disease,
history of revascularization, history of any arrhythmia) in
Table 2. Demographic and Clinical Factors Used to Predict Overall and Cardiac Survival
Attribute N Total LL Rx No LL Rx p Value
Age (yrs) 713 66.4  9.6 63.9  9.6 67.1  9.5 0.000
Female 713 118 (17%) 19 (13%) 99 (18%) 0.174
Non-white race 713 74 (10%) 4 (3%) 70 (12%) 0.000
Education level 713 0.335
High school 284 (40%) 58 (39%) 226 (40%)
College 192 (27%) 48 (32%) 144 (26%)
Graduate school 22 (3%) 5 (3%) 17 (3%)
Health insurance 710
Private 269 (38%) 56 (38%) 213 (38%) 1.00
HMO 108 (15%) 25 (17%) 83 (15%) 0.521
VA-military 80 (11%) 19 (13%) 61 (11%) 0.469
Medicare-Medicaid 438 (62%) 91 (61%) 347 (62%) 1.00
None 28 (4%) 4 (3%) 24 (4%) 0.482
Income 387 0.358
20K 206 (53%) 41 (44%) 165 (56%)
20–50K 150 (39%) 43 (46%) 107 (37%)
50K 31 (8%) 10 (11%) 21 (7%)
Index arrhythmia 713 0.022
VF 283 (40%) 48 (32%) 235 (42%)
Documented VT, syncope 150 (21%) 28 (19%) 122 (22%)
Symptomatic sustained VT 280 (39%) 73 (49%) 207 (37%)
Arrhythmia prior to index VT/VF 713
Any 352 (49%) 67 (45%) 285 (51%) 0.230
Prior VF 31 (4%) 5 (3%) 26 (5%) 0.653
Prior VT 111 (16%) 26 (17%) 85 (15%) 0.529
Prior Afib/Aflutter 164 (23%) 27 (18%) 137 (24%) 0.126
Bradycardia requiring Rx 42 (6%) 7 (5%) 35 (6%) 0.563
LVEF 708 0.31  0.12 0.31  0.11 0.31  0.13 0.776
Follow-up (months) 713 28.1  12.4 28.0  10.7 28.1  12.8 0.393
ICD (randomized) 713 353 (50%) 80 (54%) 273 (48%) 0.270
Class III CHF (baseline) 713 57 (8%) 13 (9%) 44 (8%) 0.735
History of 713
PVD 124 (17%) 21 (14%) 103 (18%) 0.274
CVD 104 (15%) 28 (19%) 76 (13%) 0.117
Renal disease 58 (8%) 9 (6%) 49 (9%) 0.399
Arthritis 132 (19%) 22 (15%) 110 (20%) 0.195
COPD 114 (16%) 18 (12%) 96 (17%) 0.167
MI 578 (81%) 137 (92%) 441 (78%) 0.000
CHF 321 (45%) 63 (42%) 258 (46%) 0.461
HT 409 (57%) 98 (66%) 311 (55%) 0.020
Diabetes 184 (26%) 37 (25%) 147 (26%) 0.833
Revascularization prior to index VT/VF 713 92 (13%) 13 (9%) 79 (14%) 0.099
Baseline revascularization 713 310 (43%) 85 (57%) 225 (40%) 0.000
Present smoker 713 149 (21%) 35 (23%) 114 (20%) 0.428
Discharge meds 713
Beta-blocker 228 (32%) 56 (38%) 172 (30%) 0.114
Digitalis 297 (42%) 48 (32%) 249 (44%) 0.009
ACE inhibitor 488 (68%) 117 (79%) 371 (66%) 0.003
Nitrate 286 (40%) 73 (49%) 213 (38%) 0.015
Antiplatelet Rx 471 (66%) 111 (74%) 360 (64%) 0.015
Data presented as mean  SD or N(%) for the total study population (Total), for the subgroup receiving lipid-lowering drug
therapy (LL Rx), and for the subgroup not receiving lipid-lowering therapy (no LL Rx). Baseline revascularization indicates
revascularization procedure (coronary artery bypass grafting or percutaneous coronary intervention) after index VT/VF episode
that was accomplished prior to randomization in the AVID trial.
ACE  angiotensin-converting enzyme; Afib  atrial fibrillation; Aflutter  atrial flutter; CABG  coronary artery bypass
graft surgery; Class III CHF (baseline)  New York Heart Association heart failure function class III at baseline; CHF 
congestive heart failure; COPD  chronic obstructive pulmonary disease; CVD  cerebrovascular disease; HMO  health
maintenance organization; HT  hypertension; ICD (randomized)  randomized to receive an implantable cardioverter
defibrillator in the AVID study; LVEF  left ventricular ejection fraction; meds  medications; MI  myocardial infarction;
PVD  peripheral vascular disease; Rx  treatment; VA  Veterans Affairs; VF  ventricular fibrillation; VT  ventricular
tachycardia.
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the total study group did not alter these results (adjusted
p  0.03). The reduction in relative hazard for all-cause
mortality associated with lipid-lowering drug therapy was
0.36 (95% CI 0.15 to 0.68).
Kaplan-Meier estimates of cardiac-death free survival for
the total study group are shown in Figure 3. The univariate
association between survival and the use of lipid-lowering
drugs was statistically significant (p  0.02). Similar pat-
terns of survival as a function of use of lipid-lowering drug
therapy were seen in each of the randomized AVID treat-
ment arms, but the differences in the smaller subgroups did
not reach statistical significance (p  0.13 in the ICD arm,
p  0.11 in the antiarrhythmic drug arm). Adjustment for
inequities in baseline determinants of survival in the total
study group did not alter these results (adjusted p  0.04).
The reduction in relative hazard for cardiac death associated
with lipid-lowering drug therapy was 0.39 (95% CI 0.16 to
0.78).
DISCUSSION
This study of patients with ASHD being treated for
life-threatening VT/VF with an ICD finds a strong asso-
ciation between the use of lipid-lowering drug therapy and
freedom from VT/VF recurrence. The use of lipid-lowering
drug therapy was associated with a 40% reduction in the
relative hazard for VT/VF recurrence. Similarly, lipid-
lowering drug therapy was also associated with a 36%
reduction in the relative hazard for death and a 39%
reduction in the relative hazard for cardiac death in patients
Figure 1. Kaplan-Meier survival curves for the outcome of freedom from ventricular tachyarrhythmia recurrence in patients with an implantable cardioverter
defibrillator as a function of whether lipid-lowering drug therapy was not used (dashed line, no LL Rx) or was used early and consistently (solid line, LL
Rx). VT/VF  ventricular tachycardia/ventricular fibrillation.
Figure 2. Kaplan-Meier survival curves for the outcome of freedom from all-cause mortality as a function of whether lipid-lowering drug therapy was not
used (dashed line, no LL Rx) or was used early and consistently (solid line, LL Rx).
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with ASHD treated for life-threatening VT/VF with either
antiarrhythmic drug therapy or ICD therapy.
Relative to the prevention of death or cardiac death, the
present results support the previous literature in the general
population of patients with or at risk to develop atheroscle-
rotic coronary artery disease (3–6). Nevertheless, it is
noteworthy that magnitude of the survival benefit associated
with lipid-lowering therapy in patients with a demonstrated
propensity to life-threatening VT/VF is higher than that
generally reported from mortality trials in patients without a
demonstrated propensity to life-threatening VT/VF (3–6).
Furthermore, this benefit is expressed early in follow-up.
These observations support the possibility that direct or
indirect antiarrhythmic effects of lipid-lowering therapy
contribute to a greater and earlier benefit in patients with
life-threatening VT/VF.
Relative to the prevention of VT/VF recurrences, the
present results also support De Sutter et al.’s report (8) that
lipid-lowering therapy decreases the probability of VT/VF
recurrences in patients treated with an ICD. That study
compared the VT/VF recurrence rates of 27 patients with
ASHD who had received an ICD after experiencing a
life-threatening VT/VF who were also receiving lipid-
lowering therapy with those of 51 similar patients who were
not also receiving lipid-lowering therapy. As in the present
analysis, the delivery of an appropriate ICD therapy was
considered to represent a VT/VF recurrence. De Sutter et
al. (8) reported that six of the 27 patients (22%) who
received lipid-lowering therapy and 29 of the 51 patients
(57%) who did not receive lipid-lowering therapy received
an appropriate ICD shock (p  0.004) over a mean
follow-up period of 16.1  10.5 months. This difference
suggested a relative risk reduction of 0.61 (95% CI 0.34 to
0.77) associated with lipid-lowering therapy. Although this
difference persisted in a multivariate analysis, that analysis
was limited in terms of covariates given its small sample size.
The results of the present analysis refine the point estimate
of the apparent association between lipid-lowering therapy
and VT/VF recurrences after correction for a wider range of
baseline differences in VT/VF recurrence risk factors, and
indicate a more conservative reduction in the relative risk of
VT/VF recurrence of approximately 43% by 16.1 months.
There are a number of potential mechanisms by which
lipid-lowering drug therapy could reduce VT/VF recur-
rences in this study population. Lipid-lowering therapy has
been demonstrated to prevent progression and, in some
patients, to promote regression of atherosclerotic plaques
(12). Experimental data suggest that lipid-lowering therapy
modifies the lipid content of high-risk plaques, thereby
stabilizing them and preventing plaque rupture (13). Lipid-
lowering therapy, especially with HMG-CoA reductase
inhibitors, also improves coronary artery endothelial func-
tion (14). Improvement in coronary artery endothelial func-
tion would reduce the probability of plaque rupture, thereby
preventing the ischemia-induced electrophysiologic effects
that predispose to VT/VF (15). Furthermore, the antioxi-
dant effects of some lipid-lowering drugs could inhibit
ischemia-induced development of the oxygen free radicals
that lead to sarcoplasmic injury and intracellular calcium
overload, which may be important contributors to the
development of VT/VF (16). Finally, therapy with an
HMG-CoA reductase inhibitor has also been reported to
beneficially affect disordered autonomic control of cardio-
vascular function (17).
These potential indirect antiarrhythmic effects of lipid-
lowering therapy notwithstanding, such therapy may also
have more direct antiarrhythmic effects. Lipid-lowering
drug therapy modulates the fatty acid composition and
Figure 3. Kaplan-Meier survival curves for the outcome of freedom from cardiac mortality as a function of whether lipid-lowering drug therapy was not
used (dashed line, no LL Rx) or was used early and consistently (solid line, LL Rx).
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physiochemical properties of the sarcolemma, with resultant
alterations in transmembrane ion channel properties (18–
20). Changes in these properties affect ventricular conduc-
tion and excitability (21,22). Thus, it is possible that
lipid-lowering drug therapy has direct effects on cardiac ion
channel function contributing to the prevention of the
development of VT/VF during acute ischemia or in the
setting of ventricular dysfunction (23).
Study limitations. The major limitation of the present
study is the nonrandom allocation of patients to those who
did and to those who did not receive lipid-lowering therapy.
Instead, such therapy was prescribed or not prescribed
according to the perception of need by each patient’s
attending physician(s). Accordingly, the populations of
patients who did and who did not receive lipid-lowering
therapy differ in ways that may also impact prognosis. After
adjustment for these baseline differences in multivariate
analysis, patients in the AVID study who received lipid-
lowering therapy had a lower incidence of VT/VF recur-
rences, cardiac death, and all-cause mortality. Nevertheless,
these data, particularly the newer observation of a decreased
incidence of VT/VF recurrences, must be considered to be
hypothesis-generating until confirmed in a randomized,
controlled clinical trial.
Conclusions. The use of lipid-lowering drug therapy in
patients with ASHD who are being treated for life-
threatening VT/VF is associated with a substantial reduc-
tion in both all-cause mortality and cardiac death. Further-
more, lipid-lowering drug therapy in this setting is also
associated with a substantial reduction in the probability of
VT/VF recurrences.
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